Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.

NCT ID: NCT00921115

Last Updated: 2023-05-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 42 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-05-31
• Study Completion Date: 2023-03-20

Brief Summary

This study is being done to test the safety and effectiveness of two drugs, Anastrozole and Fulvestrant, used as combined therapy in the neo-adjuvant setting for hormone receptor positive invasive breast cancer.

Detailed Description

Hormonal therapies are generally preferred treatments of breast cancer because they have minimal side effects. Hormone receptor positive breast cancer generally does not respond very well to chemotherapy, which has many side effects. Hormonal therapy with a single drug such as Anastrozole is the main type of treatment used to reduce the risk of cancer recurrence. Whether a combination of Anastrazole nad Fulvestrant is effective and feasible is not known. This study is being done to answer this question.

This is a phase II single arm study. Patients will have an Oncotype Dx performed and only if the recurrence score is low or intermediate, they would be eligible. Eligible patients will receive Anastrazole and Fulvestrant for 16 week.

Subjects will receive Anastrazole 1 mg po q day and Fulvestrant 500 mg IM, day 1, day 14, day 28 and thereafter once every 28 days on outpatient basis. On day 28, subjects will be evaluated for side effects and clinically and a needle core biopsy (optional) will be obtained. If there is increase in Ki 67 by 50%, subjects will be taken off the study. Response evaluation will occur every 28 days during outpatient clinic visits. All treatment will continue until 4 months when patients will undergo surgical intervention. After surgery, patients will be off study and will receive additional breast cancer therapy at the discretion of their treating physician. Patients who develop progressive disease on protocol will be removed from the study and will then be treated at the discretion of the treating physician. The protocol will be closed after the last accrued patient has had surgery.

Conditions

Invasive Breast Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arimidex + Faslodex

Patients will have an Oncotype Dx performed and if the RS is <25, they will receive Anastrazole and Fulvestrant for 16 weeks.

On day 28, subjects will be evaluated for side effects and a needle core biopsy (optional) will be obtained. Response evaluation will occur every 28 days. All treatment will continue for 4 months followed by breast surgery. After surgery, patients will be off study and will receive additional breast cancer therapy per their treating physician. Patients who develop progressive disease on protocol will be removed from the study and treated by their treating physician. The protocol will be closed after the last accrued patient has had surgery.

Group Type: EXPERIMENTAL

Fulvestrant

Intervention Type: DRUG

Fulvestrant IM on day 14 and on day 28 followed by day 28 of all subsequent cycles thereafter. Treatment will be continued for a total of 4 cycles.

Anastrazole

Intervention Type: DRUG

Anastrazole, 1mg by mouth every day of all 28 day cycles and continued for a total of 4 cycles

Interventions

Fulvestrant

Fulvestrant IM on day 14 and on day 28 followed by day 28 of all subsequent cycles thereafter. Treatment will be continued for a total of 4 cycles.

Intervention Type: DRUG

Anastrazole

Anastrazole, 1mg by mouth every day of all 28 day cycles and continued for a total of 4 cycles

Intervention Type: DRUG

Other Intervention Names

Faslodex; Arimidex

Eligibility Criteria

Inclusion Criteria

• Female patient > 18 years of age.
• Histologically proven invasive adenocarcinoma of the breast.
• Patients must be candidates for neoadjuvant treatment (Tumor size > 2cm and/or clinical N1 or N2).
• ER positive (> 10% of cells) and/or PgR positive (> 10% of the cells) and HER-2 negative disease (IHC 0 or 1+ and/or FISH negative, IHC 2+ and FISH negative)
• Menopausal status

• Patients must be post-menopausal as defined by one of the following criteria:

• Prior bilateral oophorectomy
• 12 months since LMP with no prior hysterectomy
• Patients > 55 years with prior hysterectomy
• Patients < 55 years of age and with a prior hysterectomy without oophorectomy, estradiol and FSH levels must be consistent with the patient being postmenopausal.
• Premenopausal or perimenopausal women who do not meet the postmenopausal criteria above are also eligible, but are required to undergo ovarian suppression with an LHRH agonist. Ovarian suppression can be initiated any time prior to or on day 1 of protocol therapy and must continue throughout protocol therapy.
• Performance status of 2 or better per SWOG criteria
• No prior chemotherapy or endocrine therapy for the current cancer diagnosis.
• If female of childbearing potential, pregnancy test is negative prior to initiation of ovarian suppression.
• Patients must be informed of the investigational nature of the study, and must sign an informed consent in accordance with the institutional rules.
• Oncotype Dx Recurrence Score </= 25.

Exclusion Criteria

• Patients with metastatic disease.
• The presence of any other medical or psychiatric disorder that, in the opinion of the treating physician, would contraindicate the use of drugs in this protocol or place the subject at undue risk for treatment complications.
• Premenopausal without ovarian suppression.
• Pregnancy or lactation.
• Patients with concomitant or previous malignancies within the last 5 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
• Patients with emotional limitations are excluded from study
• Platelets less than 100 x 109 /L
• Total bilirubin greater than 1.5 x ULRR
• ALT or AST greater than 2.5 x ULRR
• History of bleeding diathesis (i.e., disseminated intravascular coagulation [DIC], clotting factor deficiency) or long-term anticoagulant therapy (other than antiplatelet therapy).
• History of hypersensitivity to active or inactive excipients of fulvestrant (i.e. castor oil or Mannitol).
• Oncotype Dx Recurrence Score of >25.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: collaborator

University of Kansas Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Qamar Khan, MD

Role: PRINCIPAL_INVESTIGATOR

University of Kansas Medical Center

Locations

University of Kansas Medical Center

Kansas City, Kansas, United States

Countries

United States

Other Identifiers

IRUSANAS0092

Identifier Type: OTHER

Identifier Source: secondary_id

11595

Identifier Type: -

Identifier Source: org_study_id